• Company
• Half of pts with macular degeneration have ↓ effect
• by Sep 26, 2022 06:07am

• Policy
• HCV treatment Epclusa·Vosevi start pricing negotiations
• by Lee, Tak-Sun Sep 23, 2022 05:52am

• Company
• Nubeqa can be prescribed at general hospitals
• by Eo, Yun-Ho Sep 23, 2022 05:52am

• Policy
• On-site inspections of overseas plants will resume next year
• by Lee, Hye-Kyung Sep 23, 2022 05:52am

• Policy
• Leclaza to receive first monitoring for PVA negotiations
• by Lee, Tak-Sun Sep 23, 2022 05:52am

• Opinion
• [Reporter's view]Bio-Administrative Orders of the USA
• by Kim, Jin-Gu Sep 23, 2022 05:51am

• Company
• Aricept grows to make ₩70B ... Ebixa nears ₩15B
• by Nho, Byung Chul Sep 22, 2022 06:02am

• Policy
• Janssen's Imbruvica succeeded in setting a standard
• by Lee, Tak-Sun Sep 22, 2022 06:02am

• Company
• Moderna releases first Omicron-specific vaccine, Spikevax-2
• by Sep 22, 2022 06:02am

• Company
• Hanmi Poziotinib has greater patient benefits than risks
• by Nho, Byung Chul Sep 22, 2022 06:02am